Abstract: OBJECTIVE With Poloxamer 407(P407) as the carrier， doxorubicin-copper-curcumin ternary complex was encapsulated in the micelles to achieve quantitative and intelligent drug release behavior and synergistic effect. METHODS With P407 as the carrier，the preparing technology was optimized by Box-Behnken design and the in vitro pH-sensitive drug release behavior of DOX-Cu-Cur/P407 was examined; the MTT analysis was carried out to evaluate the cytotoxicity to tumor cells. RESULTS Under the optimum condition， the encapsulation efficiency of doxorubicin and curcumin was (93.17 ± 1.05)% and (100.03 ± 1.10)%， size distribution was (31.06 ± 4.20) nm，PDI is 0.174 ± 0.028. Meantime， in vitro drug release test showed the DOX-Cu-Cur/P407 micelles was pH-sensitive. The MTT analysis showed DOX-Cu-Cur/P407 micelles could significantly inhibit the tumor cells with a better synergistic effect compared with free drugs. CONCLUSION The optimal DOX-Cu-Cur/P407 micelle is uniform in size and has satisfactory encapsulation efficiency. Meanwhile it is sensitive to acidic microenvironment of tumor and can achieve the purpose of quantitative and intelligent drug release.